Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

This study aims to evaluate the safety and efficacy of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 (TRBC1/2 CAR-NK cells) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL).

Trial Details

NCT ID

NCT07164560

Phase

PHASE1

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Anti-TRBC1 CAR-T cells

Locations (sample)

Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

According to the 2016 WHO classification of lymphoid neoplasms, patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) must meet the f…
Voluntarily agree to participate in this study and provide signed informed consent.
Age 18 to 75 years, male or female.
Diagnosis of relapsed/refractory PTCL, defined as failure of ≥1 prior line of therapy. Eligible histologic subtypes include (but are not limited to):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →